Home › Companies › Apogee Therapeutics, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Apogee Therapeutics, Inc.’s Form 8-K, filed June 12, 2026 (Item 5.07 on EDGAR). Page generated October 25, 2026.
Meeting of June 9, 2026: 5 items on Apogee Therapeutics, Inc.’s Form 8-K, filed June 12, 2026: 2 approved · 3 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2024-2025 2025-2026
Explore Apogee Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Apogee Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 12, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Mark C. McKenna | 53,689,547 | -- | -- | 1,515,704 | 1,795,532 | 97% | Not verified | — |
| Elect Director: Jennifer Fox | 52,895,552 | -- | -- | 2,309,699 | 1,795,532 | 96% | Not verified | — |
| Elect Director: William (BJ) Jones, Jr. | 44,964,804 | -- | -- | 10,240,447 | 1,795,532 | 81% | Not verified | — |
| 2. Ratification of Independent Auditor Appointment The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 | 56,960,778 | 1,361 | 38,644 | -- | -- | 99.9% | Approved | — |
| 3. Approval on a Non-Binding, Advisory Basis of the Compensation of our Named Executive Officers The compensation of our named executive officers as disclosed in the Proxy Statement | 54,324,725 | 633,959 | 246,567 | -- | 1,795,532 | 99% | Approved | — |
Source: Apogee Therapeutics, Inc., Form 8-K, filed with the SEC on June 12, 2026 — read the filing on EDGAR.
Each item below shows how the 257 asset managers that disclosed a Apogee Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 6 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: Election of Class III Directors for terms expiring in 2029: Jennifer Fox
Apogee Therapeutics, Inc.’s own tally for this item (“Elect Director: Jennifer Fox”): 52,895,552 for, 2,309,699 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 7,760,790 | 0 | 0 | 0 | For |
| Fidelity | 6,673,905 | 0 | 0 | 0 | For |
| Vanguard | 5,230,990 | 0 | 5 | 2,311 | For |
| Jackson National | 1,439,376 | 0 | 0 | 0 | For |
| BlackRock | 1,155,224 | 0 | 0 | 0 | For |
| State Street | 681,648 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 568,792 | 0 | 0 | 0 | For |
| JPMorgan | 491,100 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 422,457 | Withhold |
| Voya | 391,219 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 380,003 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 379,608 | 0 | 0 | 0 | For |
| Federated Hermes | 365,125 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 362,287 | 0 | 0 | 0 | For |
| Capital Group | 348,674 | 0 | 0 | 0 | For |
| AllianceBernstein | 312,167 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 267,924 | 0 | 0 | 0 | For |
| Prudential/PGIM | 245,742 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 216,119 | 0 | 0 | 0 | For |
| Hartford | 212,162 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 207,913 | 0 | 0 | 0 | For |
| John Hancock | 201,321 | 0 | 0 | 0 | For |
| Loomis Sayles | 0 | 0 | 197,794 | 0 | Abstain |
| Equitable | 174,600 | 0 | 0 | 0 | For |
| Victory Capital | 161,964 | 0 | 0 | 0 | For |
Fund voting reports, all 83 managers: 29,449,932 for, 574,794 withheld, 224,807 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Remedium Capital Partners, LLC | 583,591 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 583,591 for.
Combines 7 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: Election of Class III Directors for terms expiring in 2029: Mark C. McKenna
Apogee Therapeutics, Inc.’s own tally for this item (“Elect Director: Mark C. McKenna”): 53,689,547 for, 1,515,704 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 7,760,790 | 0 | 0 | 0 | For |
| Fidelity | 6,673,905 | 0 | 0 | 0 | For |
| Vanguard | 5,230,995 | 0 | 0 | 2,311 | For |
| Jackson National | 1,439,376 | 0 | 0 | 0 | For |
| BlackRock | 1,155,224 | 0 | 0 | 0 | For |
| State Street | 2,196 | 0 | 0 | 679,452 | Withhold |
| MUTUAL FUND SERIES TRUST | 568,792 | 0 | 0 | 0 | For |
| JPMorgan | 491,100 | 0 | 0 | 0 | For |
| Charles Schwab | 422,457 | 0 | 0 | 0 | For |
| Voya | 391,219 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 378,903 | 0 | 0 | 1,100 | For |
| JANUS INVESTMENT FUND | 379,608 | 0 | 0 | 0 | For |
| Federated Hermes | 365,125 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 362,287 | 0 | 0 | 0 | For |
| Capital Group | 348,674 | 0 | 0 | 0 | For |
| AllianceBernstein | 312,167 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 267,924 | 0 | 0 | 0 | For |
| Prudential/PGIM | 245,742 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 216,119 | 0 | 0 | 0 | For |
| Hartford | 212,162 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 207,913 | 0 | 0 | 0 | For |
| John Hancock | 201,321 | 0 | 0 | 0 | For |
| Loomis Sayles | 197,794 | 0 | 0 | 0 | For |
| Equitable | 174,600 | 0 | 0 | 0 | For |
| Victory Capital | 161,964 | 0 | 0 | 0 | For |
Fund voting reports, all 83 managers: 29,521,898 for, 727,636 withheld. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Remedium Capital Partners, LLC | 583,591 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 583,591 for.
Combines 6 wordings of this item as funds reported it.
81% Majority: yes · of votes cast
Description as filed by funds: Election of Class III Directors for terms expiring in 2029: William (BJ) Jones, Jr.
Apogee Therapeutics, Inc.’s own tally for this item (“Elect Director: William (BJ) Jones, Jr.”): 44,964,804 for, 10,240,447 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 7,760,790 | 0 | 0 | 0 | For |
| Fidelity | 6,656,623 | 0 | 0 | 17,282 | For |
| Vanguard | 5,233,291 | 0 | 15 | 0 | For |
| Jackson National | 1,391,936 | 0 | 47,440 | 0 | For |
| BlackRock | 289,309 | 0 | 865,915 | 0 | Mixed |
| State Street | 1,387 | 0 | 0 | 680,261 | Withhold |
| MUTUAL FUND SERIES TRUST | 557,423 | 0 | 0 | 11,369 | For |
| JPMorgan | 491,100 | 0 | 0 | 0 | For |
| Charles Schwab | 422,457 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 0 | 391,219 | Withhold |
| PENN SERIES FUNDS INC | 378,903 | 0 | 0 | 1,100 | For |
| JANUS INVESTMENT FUND | 379,608 | 0 | 0 | 0 | For |
| Federated Hermes | 365,125 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 67,914 | 0 | 294,373 | 0 | Mixed |
| Capital Group | 348,674 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 0 | 312,167 | Withhold |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 267,924 | Withhold |
| Prudential/PGIM | 243,487 | 0 | 0 | 2,255 | For |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 0 | 216,119 | Withhold |
| Hartford | 212,162 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 207,913 | Withhold |
| John Hancock | 190,379 | 0 | 10,942 | 0 | Mixed |
| Loomis Sayles | 197,794 | 0 | 0 | 0 | For |
| Equitable | 8,636 | 0 | 0 | 165,964 | Withhold |
| Victory Capital | 583 | 0 | 0 | 161,381 | Withhold |
Fund voting reports, all 83 managers: 26,037,967 for, 2,862,461 withheld, 1,349,106 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Remedium Capital Partners, LLC | 583,591 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 583,591 for.
Combines 9 wordings of this item as funds reported it.
99% Approved · of votes cast
Description as filed by funds: Approval, on a non-binding advisory basis, of the compensation of our named executive officers as disclosed in the proxy statement.
Apogee Therapeutics, Inc.’s own tally for this item (“3. Approval on a Non-Binding, Advisory Basis of the Compensation of our Named Executive Officers The compensation of our named executive officers as disclosed in the Proxy Statement”): 54,324,725 for, 633,959 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3: Approval on a Non-Binding, Advisory Basis of the Compensation of our Named Executive Officers The compensation of our named executive officers as disclosed in the Proxy Statement was approved on a non-binding, advisory basis as follows:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 7,760,790 | 0 | 0 | 0 | For |
| Fidelity | 6,673,905 | 0 | 0 | 0 | For |
| Vanguard | 5,233,305 | 0 | 0 | 0 | For |
| Jackson National | 1,439,376 | 0 | 0 | 0 | For |
| BlackRock | 1,155,224 | 0 | 0 | 0 | For |
| State Street | 681,621 | 27 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 568,792 | 0 | 0 | 0 | For |
| JPMorgan | 491,100 | 0 | 0 | 0 | For |
| Charles Schwab | 422,457 | 0 | 0 | 0 | For |
| Voya | 391,219 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 380,003 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 379,608 | 0 | 0 | 0 | For |
| Federated Hermes | 365,125 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 362,287 | 0 | 0 | 0 | For |
| Capital Group | 0 | 348,674 | 0 | 0 | Against |
| AllianceBernstein | 312,167 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 267,924 | 0 | 0 | 0 | For |
| Prudential/PGIM | 245,742 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 216,119 | 0 | 0 | 0 | For |
| Hartford | 212,162 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 207,913 | 0 | 0 | 0 | For |
| John Hancock | 201,321 | 0 | 0 | 0 | For |
| Loomis Sayles | 197,794 | 0 | 0 | 0 | For |
| Equitable | 174,600 | 0 | 0 | 0 | For |
| Victory Capital | 161,964 | 0 | 0 | 0 | For |
Fund voting reports, all 83 managers: 29,882,898 for, 348,900 against, 17,734 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 10,796,815 | 0 | 0 | 0 | For |
| Fidelity | 9,046,976 | 0 | 0 | 0 | For |
| Wellington | 3,616,416 | 0 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 2,782,097 | 0 | 0 | 0 | For |
| Janus Henderson | 2,385,756 | 0 | 0 | 0 | For |
| Venrock Adviser, LLC | 1,750,000 | 0 | 0 | 0 | For |
| BlackRock | 1,331,822 | 0 | 0 | 0 | For |
| State Street | 1,244,402 | 8,225 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,195,247 | 0 | 0 | 0 | For |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 1,152,577 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 1,019,976 | 0 | 0 | 0 | For |
| AllianceBernstein | 889,984 | 0 | 0 | 0 | For |
| Affinity Asset Advisors, LLC | 715,020 | 0 | 0 | 0 | For |
| Vestal Point Capital, LP | 668,829 | 0 | 0 | 0 | For |
| Remedium Capital Partners, LLC | 583,591 | 0 | 0 | 0 | For |
| First Light Asset Management, LLC | 537,675 | 0 | 0 | 0 | For |
| Novo Holdings A/S | 450,000 | 0 | 0 | 0 | For |
| Federated Hermes | 440,029 | 0 | 0 | 0 | For |
| Vanguard | 431,171 | 0 | 0 | 0 | For |
| Charles Schwab | 427,080 | 0 | 0 | 0 | For |
| FRONTIER CAPITAL MANAGEMENT CO LLC | 393,902 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 392,986 | 0 | 0 | 0 | For |
| Voya | 391,219 | 0 | 0 | 0 | For |
| JENNISON ASSOCIATES LLC | 353,083 | 0 | 0 | 0 | For |
| Capital Group | 0 | 348,674 | 0 | 0 | Against |
Institutional-manager reports, all 201 managers: 47,244,111 for, 485,005 against, 207,061 abstained, 122 not voted. Showing the 25 largest; see all in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2026.
Apogee Therapeutics, Inc.’s own tally for this item (“2. Ratification of Independent Auditor Appointment The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026”): 56,960,778 for, 1,361 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2: Ratification of Independent Auditor Appointment The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 was ratified as follows:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 7,760,790 | 0 | 0 | 0 | For |
| Fidelity | 6,673,905 | 0 | 0 | 0 | For |
| Vanguard | 5,233,306 | 0 | 0 | 0 | For |
| Jackson National | 1,439,376 | 0 | 0 | 0 | For |
| BlackRock | 1,155,224 | 0 | 0 | 0 | For |
| State Street | 681,648 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 568,792 | 0 | 0 | 0 | For |
| JPMorgan | 491,100 | 0 | 0 | 0 | For |
| Charles Schwab | 422,457 | 0 | 0 | 0 | For |
| Voya | 391,219 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 380,003 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 379,608 | 0 | 0 | 0 | For |
| Federated Hermes | 365,125 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 362,287 | 0 | 0 | 0 | For |
| Capital Group | 348,674 | 0 | 0 | 0 | For |
| AllianceBernstein | 312,167 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 267,924 | 0 | 0 | 0 | For |
| Prudential/PGIM | 245,742 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 216,119 | 0 | 0 | 0 | For |
| Hartford | 212,162 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 207,913 | 0 | 0 | 0 | For |
| John Hancock | 201,321 | 0 | 0 | 0 | For |
| Loomis Sayles | 197,794 | 0 | 0 | 0 | For |
| Equitable | 174,600 | 0 | 0 | 0 | For |
| Victory Capital | 161,964 | 0 | 0 | 0 | For |
Fund voting reports, all 83 managers: 30,231,799 for, 17,734 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Remedium Capital Partners, LLC | 583,591 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 583,591 for.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 74,882,396 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | T. Rowe Price | 10.36% |
| 2 | Fidelity | 8.91% |
| 3 | Vanguard | 6.99% |
| 4 | Jackson National | 1.92% |
| 5 | BlackRock | 1.54% |
| 6 | State Street | 0.91% |
| 7 | MUTUAL FUND SERIES TRUST | 0.76% |
| 8 | JPMorgan | 0.66% |
| 9 | Charles Schwab | 0.56% |
| 10 | Voya | 0.52% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | T. Rowe Price | 14.42% |
| 2 | Fidelity | 12.08% |
| 3 | Wellington | 4.83% |
| 4 | RTW INVESTMENTS, LP | 3.72% |
| 5 | Janus Henderson | 3.19% |
| 6 | Venrock Adviser, LLC | 2.34% |
| 7 | BlackRock | 1.78% |
| 8 | State Street | 1.67% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 1.60% |
| 10 | DRIEHAUS CAPITAL MANAGEMENT LLC | 1.54% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| FMR (Fidelity) | 12.37% | 13F |
| Wellington Management | 5.84% | 13F |
| BlackRock | 5.46% | 13F |
| Vanguard Group | 3.82% | 13F |
| RTW Investments, LP | 3.62% | 13G |
| State Street | 2.89% | 13F |
| Geode Capital | 1.63% | 13F |
| T. Rowe Price | 1.53% | 13F |
| JPMorgan Chase | 1.48% | 13F |
| Morgan Stanley | 1.19% | 13F |
Percentages above are of 74,882,396 shares outstanding, as reported by Apogee Therapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Apogee Therapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on October 25, 2026; a live search always shows the current data.
At Apogee Therapeutics, Inc.'s shareholder meeting held June 9, 2026, in the 2025-2026 proxy season, 257 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 1,773 separate fund positions. On the most widely held item on that ballot — Approval, on a non-binding advisory basis, of the compensation of our named executive officers… — Apogee Therapeutics, Inc.'s filing reports the proposal as approved, with 99% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Apogee Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 12, 2026.
Apogee Therapeutics, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).
Download data (CSV): ballot items · votes by manager · column guide.